| Literature DB >> 33917707 |
Rosa Anna Siciliano1, Anna Reale1, Maria Fiorella Mazzeo1, Stefano Morandi2, Tiziana Silvetti2, Milena Brasca2.
Abstract
Probiotics are live microorganisms that confer health benefits on the host. However, in recent years, several concerns on their use have been raised. In particular, industrial processing and storage of probiotic products are still technological challenges as these could severely impair cell viability. On the other hand, safety of live microorganisms should be taken into account, especially when administered to vulnerable people, such as the elderly and immunodeficient individuals. These drawbacks have enhanced the interest toward new products based on non-viable probiotics such as paraprobiotics and postbiotics. In particular, paraprobiotics, defined as "inactivated microbial cells (non-viable) that confer a health benefit to the consumer," hold the ability to regulate the adaptive and innate immune systems, exhibit anti-inflammatory, antiproliferative and antioxidant properties and exert antagonistic effect against pathogens. Moreover, paraprobiotics can exhibit enhanced safety, assure technological and practical benefits and can also be used in products suitable for people with weak immunity and the elderly. These features offer an important opportunity to prompt the market with novel functional foods or nutraceuticals that are safer and more stable. This review provides an overview of central issues on paraprobiotics and highlights the urgent need for further studies aimed at assessing safety and efficacy of these products and their mechanisms of action in order to support decisions of regulatory authorities. Finally, a definition is proposed that unambiguously distinguishes paraprobiotics from postbiotics.Entities:
Keywords: dairy foods; health benefits; immunomodulation; inactivation; non-dairy food; paraprobiotics; probiotics
Mesh:
Year: 2021 PMID: 33917707 PMCID: PMC8068161 DOI: 10.3390/nu13041225
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Current state of the scientific literature on paraprobiotics: distribution of papers published in the last 20 years in the main research areas (source: Web of Science; 2011–2020; updated to 22 December 2020).
Figure 2Technological processes for the production of paraprobiotics and their effects on bacterial cells.
Figure 3Definitions of probiotics, paraprobiotics and postbiotics together with cell components involved in biological activities.
Health benefits of bioactive inactivated probiotic cells in food products and nutraceuticals as described in the article.
| References | Microorganisms | Inactivation Treatment | Cell Concentration | Foods/ | Health Benefits |
|---|---|---|---|---|---|
| Nishida et al., 2017 |
| Heat (95 °C for 30 s) | 5.3 × 107 CFU/g | Fermented milk beverage | Amelioration of stress-related symptoms and improvement of sleep quality |
| Sawada et al., 2016 | Heat (69 °C for over 1 s + 95 °C for 30 s) | 5.3 × 107 CFU/g | Fermented milk beverage | Regulation of intestinal function | |
| Nobutani et al., 2017 | 4.8 × 107 CFU/g | Fermented milk | Alleviation of irritable bowel syndrome | ||
| Zeng et al., 2016 |
| Heat (water bath at 65 °C for 60 min) | 1 × 107–108–109 CFU/mL | Yoghurt | Prevention of epithelial |
| Berni Canani et al., 2017 | Heat (85 °C | 5.9 × 1011 CFU/g | Spray-dried fermented milk | Modulation of gut microbiota | |
| Liu et al., 2015 |
| Heat (75 °C for 4 s) | 1 × 107–108–109 CFU/mL | Yoghurt | Improvement of constipation symptoms and intestinal health |
| Rodríguez–Figueroa et al., 2013 [ |
| Heat (98 °C for 10 min) | 1 × 104–105 CFU/mL | Fermented milk | Antihypertensive and hypolipidemic effects |
| Murata et al., 2018 | Heat–killed in water | 1 × 1010–3 × 1010 CFU/mL | Cell powder | Improvement of resistance to common cold infections and maintenance of a desirable mood state | |
| Buckley et al., 2018 | Spray-dried dead cells | 5 × 109 cells/tablet, four tablets daily | Solid tablets | Control of | |
| Xiao et al., 2003 | Heat-killed, lyophilized | 5 × 109 cells/tablet, two tablets daily | Tablets | Clinical efficacy in the treatment of chronic diarrhea | |
| Sawada et al., 2019 | Heat-inactivated | 1 × 1010 cells/200 mL | Sports drink | Faster recovery from fatigue and improvement of physical and mental stress-associated symptoms in athletes | |
| Sugawara et al., 2016 | Pasteurized at 90 °C and freeze-dried | 1 × 1010 cells/200 mL | Beverage | Regulatory effect on gut environment and function | |
| Nishida et al., 2017 | Pasteurized at 90 °C and freeze-dried | 1 × 1010 cells/200 mL | Beverage | Improvement of chronic stress-associated symptoms in healthy young adults | |
| Barros et al., 2020 | Ohmic heating (8 V/cm, 95 °C for seven min, 60 Hz) | Whey-grape juice drink | Control of postprandial glycemia in healthy adults | ||
| Kotani et al., 2010 | Heat-killed (autoclave sterilization | 6 × 109 cells/125 mL | Water beverage | Acceleration of salivary immunoglobin A secretion in the elderly | |
| Shinkai et al., 2013 | Heat-killed (autoclave sterilization | 2 × 109 or 2 × 1010 cells/tablet | Tablets | Reduction of cold incidence trough mucosal immunity in the elderly | |
| Hirose et al., 2006 | Heat-killed | 50 mg LP20 (20% paraprobiotic and 80% dextrin), one capsule daily | Gelatin capsules | Enhancement of acquired immunity and improvement of the quality of life in healthy subjects |